rf-fullcolor.png

 

October 18, 2013
by Alexander Gaffney, RAC

Shutdown Over, FDA to Take Triage Approach to Workload

The US government shutdown is over, and the US Food and Drug Administration's (FDA) thousands of furloughed staff members are returning to work. But don't expect the agency to be back to full capacity for a little while yet, FDA confirmed this week.

"Effective immediately, all FDA employees are reporting to work at their regular schedules," said Steven Immergut, assistant commissioner for media affairs at FDA, to Focus. "We are prioritizing our work appropriately as we transition back to normal operations."

Among the top priorities will be resuming routine domestic and international inspections of regulated facilities, he said.

In addition, the end of the shutdown brings good news for industry. Immergut noted that the agency will now be able to accept all medical product regulatory submissions for the 2014 Fiscal Year. During the shutdown, the agency was unable to accept any applications that had not paid a fee prior to 1 October 2013, leaving many drug, medical device, and biological applications in a holding pattern.

Now any applications under the Prescription Drug User Fee Act, the Medical Device User Fee Act, the Generic Drug User Fee Act or the Biosimilar User Fee Act will be able to be accepted and processed.

"FDA is pleased that the government shutdown has ended and the agency can get back to fully resuming the important work that we do every day to protect and promote the public health," Immergut said.

×

Welcome to the new RAPS Digital Experience

We have completed our migration to a new platform and are pleased to introduce the updated site.

What to expect: If you have an existing login, please RESET YOUR PASSWORD before signing in. After you log in for the first time, you will be prompted to confirm your profile preferences, which will be used to personalize content.

We encourage you to explore the new website and visit your updated My RAPS page. If you need assistance, please review our FAQ page.

We welcome your feedback. Please let us know how we can continue to improve your experience.